ClinicalTrials.gg
CompletedNCT02499237AfterDmabUpdated Mar 11, 2019

Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation

A Phase 4 interventional study of Denosumab and Zoledronic acid in Postmenopausal Osteoporosis, sponsored by 424 General Military Hospital. Completed at 2 sites in Greece. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2019-03-11.

Sponsored by 424 General Military Hospital · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
50 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing Zoledronic Acid in Osteoporosis, Postmenopausal — none open to participants now, 1 under way, none of them phase 3. Zoledronic Acid · Osteoporosis, Postmenopausal.

Enrollment
10th of 10
57 · median 195
Started
2015
the only one that year
Phase 4
5 of 10
none open now
Registered
6th of 10
by date
Lead sponsor
1 of 10
424 General Military Hospital

Among the 10 studies testing Zoledronic Acid in Osteoporosis, Postmenopausal, this one is the 10th largest by enrollment, is the only one that started in 2015, is one of 5 in phase 4, and was the 6th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

None of the 10 studies testing Zoledronic Acid in Osteoporosis, Postmenopausal is open now. The open studies under Osteoporosis, Postmenopausal, anywhere →

About Zoledronic Acid

Zoledronic Acid: first FDA approval 2001 (ZOMETA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 50 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing Zoledronic Acid in Osteoporosis, Postmenopausal as a file.
02

Study summary

In contrast with bisphosphonates,discontinuation of denosumab results in gradual loss of bone mineral density gains. The investigators aim to evaluate whether in patients treated with denosumab, a single zoledronic acid infusion would prevent the anticipated bone loss.

Read the detailed description

Discontinuation of denosumab results in a rebound rise of bone turnover markers and gradual loss of the achieved bone mineral density gains. In contrast, bisphosphonates, such as zoledronic acid, remain within the skeleton acting for several months or even years after discontinuation while maintaining bone mineral density despite the cessation of treatment. In this study, the investigators aim to evaluate changes in bone mineral density of the lumbar spine and the femoral neck, as well as in bone turnover markers one year after treatment discontinuation both in denosumab-treated women and in denosumab-treated women who switched to zoledronic acid infusion one year before treatment discontinuation.

03

Conditions studied

  • Postmenopausal Osteoporosis

Keywords

  • osteoporosis
  • denosumab
  • zoledronic acid
  • bone mineral density
  • bone markers
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women
  • osteopenic (T-score > -2.5 but \< -1.0) after treatment with denosumab

Exclusion criteria

Exclusion Criteria:

  • secondary osteoporosis;
  • diseases that could affect bone metabolism;
  • medications that could affect bone metabolism;
  • history of any antiosteoporotic treatment other than denosumab prior to randomization
  • severe liver or kidney disease ( \< 60ml/min/1.73m2)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Active comparator
    Denosumab

    Patients with low bone mass, being treated only with denosumab in the past, who will receive another year of treatment with denosumab and subsequently discontinue treatment for one year

    Drug: Denosumab

  • Experimental
    Denosumab plus zoledronic acid

    Patients with low bone mass, being treated only with denosumab in the past, who will receive a single infusion of zoledronic acid and subsequently discontinue treatment for another year

    Drug: Zoledronic acid

Interventions

  • Treatment of low bone mass with subcutaneous injections of denosumab 60 mg every 6 months for one year

    Also known as: Prolia

  • Treatment of low bone mass with a single infusion of zoledronic acid 5 mg for one year

    Also known as: Aclasta

06

What researchers measure

Primary outcomes

  1. bone mineral density of the lumbar spine

    differences between the 2 arms in the changes of lumbar spine bone mineral density measured by dual-energy X-ray absorptiometry

    Time frame: from 12 to 24 months

Secondary outcomes

  1. bone mineral density of the femoral neck

    differences between the 2 arms in the changes of femoral neck bone mineral density measured by dual-energy X-ray absorptiometry

    Time frame: from 12 to 24 months

  2. C-terminal telopeptide of type I collagen

    differences between the 2 arms in the changes of C-terminal telopeptide of type I collagen

    Time frame: from 12 to 15, 18, 24 months

  3. propeptide of procollagen type I

    differences between the 2 arms in the changes of propeptide of procollagen type I

    Time frame: from 12 to 15, 18, 24 months

  4. bone mineral density of the lumbar spine

    differences between the 2 arms in the changes of lumbar spine bone mineral density measured by dual-energy X-ray absorptiometry

    Time frame: from baseline to 12 months

  5. bone mineral density of the femoral neck

    differences between the 2 arms in the changes of femoral neck bone mineral density measured by dual-energy X-ray absorptiometry

    Time frame: from baseline to 12 months

07

Study locations

2 sites
  • 251 Airforce & VA General Hospital
    Athens, 11525, Greece
  • 424 General Military Hospital
    Thessaloniki, 56429, Greece
08

References and documents

Publications

  • Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008 Aug;43(2):222-229. doi: 10.1016/j.bone.2008.04.007. Epub 2008 Apr 26. PubMed 18539106 ↗
  • Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011 Apr;96(4):972-80. doi: 10.1210/jc.2010-1502. Epub 2011 Feb 2. PubMed 21289258 ↗
  • Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? N Engl J Med. 2012 May 31;366(22):2051-3. doi: 10.1056/NEJMp1202623. Epub 2012 May 9. No abstract available. PubMed 22571169 ↗
  • Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis--where do we go from here? N Engl J Med. 2012 May 31;366(22):2048-51. doi: 10.1056/NEJMp1202619. Epub 2012 May 9. No abstract available. PubMed 22571168 ↗
  • Anastasilakis AD, Polyzos SA, Yavropoulou MP, Appelman-Dijkstra NM, Ntenti C, Mandanas S, Papatheodorou A, Makras P. Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation. Calcif Tissue Int. 2021 May;108(5):587-594. doi: 10.1007/s00223-020-00785-1. Epub 2021 Jan 2. PubMed 33386953 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Nov 2018, 40 months.

Of 27 phase 4 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's 40 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2015
First posted
Jul 16, 2015
StartActual
Jul 2015
Primary completionActual
Nov 2018
CompletionActual
Nov 26, 2018
Last update
Mar 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02499237
Lead sponsor
424 General Military Hospital
Collaborators
251 Hellenic Air Force & VA General Hospital, Leiden University Medical Center
Responsible party
Athanasios D. Anastasilakis (Consultant of Endocrinology, 424 General Military Hospital) — Principal investigator
First posted
Jul 16, 2015
Start date
Jul 2015
Primary completion
Nov 2018
Completion
Nov 26, 2018
Last update
Mar 11, 2019

Study contacts

Athanasios D Anastasilakis, PhD
principal investigator · 424 General Military Hospital, Thessaloniki, Greece
Polyzois Makras, PhD
principal investigator · 251 Airforce and VA General Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zoledronic Acid

Start the discussion